Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer stem cells.

Anne T Collins1, Norman J Maitland

  • 1University of York, YCR Cancer Research Unit, Department of Biology, Heslington, York YO10 5DD, UK. ac43@york.ac.uk

European Journal of Cancer (Oxford, England : 1990)
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.

British journal of cancer·2026
Same author

FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.

Cancer medicine·2025
Same author

ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.

The Journal of pathology·2023
Same author

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.

Oncogene·2023
Same author

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Molecular cancer·2022
Same author

ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.

FEBS open bio·2022
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Prostate cancer remains incurable for advanced cases. Targeting cancer stem cells, distinct from normal cells, offers a promising therapeutic strategy for improved outcomes.

Area of Science:

  • Urology
  • Oncology
  • Cancer Biology

Background:

  • Prostate cancer is the most common cancer diagnosed in men, with limited effective therapies for advanced stages.
  • Current treatments like androgen ablation, chemotherapy, and radiotherapy show initial response but often lead to fatal, treatment-resistant tumors.
  • Metastatic prostate cancer is currently incurable with existing strategies.

Purpose of the Study:

  • To explore the role of cancer stem cells (CSCs) in prostate tumor biology, initiation, and progression.
  • To investigate the potential of targeting CSCs as a crucial therapeutic strategy.
  • To understand the differences between CSCs and normal stem cells for selective targeting.

Main Methods:

  • Review of recent reports on cancer stem cells and their involvement in prostate cancer.

Related Experiment Videos

  • Analysis of the potential contribution of normal stem/progenitor cells to tumor development.
  • Conceptual framework for understanding CSC biology in relation to normal stem cells.

    • Main Results:

    • Cancer stem cells are implicated in prostate tumor initiation, progression, and resistance to therapy.
    • CSCs are hypothesized to be the driving force behind treatment failure in advanced prostate cancer.
    • Understanding CSC biology is key to developing novel treatment approaches.

    Conclusions:

    • Targeting cancer stem cells is a potentially crucial strategy for improving prostate cancer treatment outcomes.
    • Differentiating CSCs from normal stem cells is essential for developing selective and effective therapies.
    • Further research into CSC biology may lead to the elimination of these cells and better therapeutic results.